Exemestane — Drug Intelligence | 46 EU Trials

Filter these 46 trials by condition, phase, country and more.

Open in Search →

46 Registered trials

25 Recruiting

18 Completed trials

34 Sponsors

23 Countries

Phase III

Phase II

Phase IV

Phase III: 22 Phase II/III: 1 Phase II: 16 Phase III/IV: 2 Phase IV: 5

Oversight events:

1 temporary halt 1 urgent safety measure 1 unexpected event 1 corrective measure across 4 trials

View oversight register →

Indications tested

Hormone receptor positive HER2 negative breast cancer 8 Breast cancer 5 Breast cancer metastatic 3 Hormone receptor positive breast cancer 2 Breast cancer female 2 Hormone receptor positive HER2 positive breast cancer 1 Ovarian cancer recurrent 1 HER2 positive breast cancer 1 Ovarian cancer 1 HER2 negative breast cancer 1 Lobular breast carcinoma in situ 1 Hormone refractory breast cancer 1

Sponsors using this IMP

Unicancer 6 AstraZeneca AB 3 European Organisation For Research And Treatment Of Cancer 2 F. Hoffmann-La Roche AG 2 Fundacion Grupo Espanol De Investigacion En Cancer De Mama 2 Medica Scientia Innovation Research S.L. 2 Pfizer Inc. 2 Region Oerebro Laen 2 Alliance Foundation Trials LLC 1 Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone 1 Cancer Trials Ireland 1 Centre Leon Berard 1

All trials — page 2

46 total

CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Phase IV 1 country Institut Für Frauengesundheit GmbH
ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz… Recruiting

2023-508094-88-00 Phase III 1 country University Of Florence
Trial that evaluates the interest of interruption versus maintaining the treatment of aromatase inhibitors in patients with metastatic low g… Recruiting

2024-512629-97-00 Phase II 1 country Centre Leon Berard
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Phase IV 1 country Grupo Espanol De Investigacion En Cancer De Mama
A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended

2022-503001-38-01 Phase III 2 countries Novartis Pharma AG
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm… Ended

2024-519087-41-00 Phase III 1 country IRCCS Ospedale Policlinico San Martino
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II… Ended

2024-516530-36-00 Phase III 1 country Cancer Trials Ireland
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Phase III 5 countries Alliance Foundation Trials LLC
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Ended

2022-502046-28-00 Phase III 7 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended

2023-506821-12-00 Phase III 4 countries Genentech Inc.
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 Phase III 14 countries Astrazeneca AB
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Phase II 1 country Unicancer
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Phase III 8 countries F. Hoffmann-La Roche AG
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended

2024-511209-49-00 Phase IV 1 country Universitaetsklinikum Ulm AöR
Multi-drug treatment for breast cancer patients with brain metastases Ended

2024-510703-11-00 Phase II 1 country Unicancer
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended

2023-506786-63-00 Phase III 8 countries Eli Lilly & Co.
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended

2023-505223-31-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 Phase III 1 country Unicancer
PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation … Ended

2024-519019-32-00 Phase II 1 country Karolinska University Hospital
"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended

2024-515368-29-00 Phase III 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients… Ended

2024-511295-33-00 Phase II 1 country Medica Scientia Innovation Research S.L.
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Phase III 14 countries Pfizer Inc.

Showing 25–46 of 46 trials

← All drugs A–Z